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Abstract 
Activation-induced cytidine deaminase (AID) induces somatic mutations in various host 
genes of non-lymphoid tissues, thereby contributing to carcinogenesis. We recently demonstrated 
that Helicobacter pylori infection and/or proinflammatory cytokine stimulation triggers aberrant 
AID expression in gastric epithelial cells, causing mutations in the tumour-suppressor TP53 gene. 
The findings of the present study provide evidence of ectopic AID expression in Barrett’s 
oesophagus and Barrett’s oesophageal adenocarcinoma, a cancer that develops under chronic 
inflammatory conditions. Immunoreactivity for endogenous AID was observed in 24 of 28 
(85.7%) specimens of the columnar-cell lined Barrett’s oesophagus and in 20 of 22 (90.9%) of 
Barrett’s adenocarcinoma, while weak or no AID protein expression was detectable in normal 
squamous epithelial cells of the oesophagus. We validated these results by analyzing tissue 
specimens from another cohort comprising 16 cases with Barrett’s oesophagus and 4 cases with 
Barrett’s adenocarcinoma. In vitro, treatment of human non-neoplastic oesophageal 
squamous-derived cells with sodium salt deoxycholic acid induced ectopic AID expression via 
the NF-B activation pathway. These findings suggest that aberrant AID expression occurs in a 
substantial proportion of Barrett’s epithelium, at least in part due to bile acid stimulation. 
Considering the genotoxic activity of AID, our current findings suggest that aberrant AID 
expression might enhance the susceptibility to genetic alterations in Barrett’s columnar-lined 
epithelial cells, leading to cancer development.  
 
Introduction 
Chronic inflammation has a critical role in the development of many human cancers (1-4), 
such as hepatitis-associated hepatocellular carcinoma, colitis-associated colorectal cancers, 
cholangitis-related cholangiocarcinoma, and Helicobacter pylori (H. pylori) infection-related 
gastric cancers (3). Several studies have demonstrated various alterations in tumour-related genes 
in inflamed tissues before cancer onset (2, 3, 5). We previously demonstrated a substantial 
number of nucleotide alterations in the tumour suppressor TP53 gene in nontumourous epithelial 
tissues of patients with chronic hepatitis (6) or H. pylori -related chronic gastritis (7). Although 
the molecular mechanisms underlying the transition from chronic inflammation to the 
accumulation of genetic mutations leading to tumourigenesis remain unknown, the discovery of 
nucleotide-editing enzymes that potentiate the genetic changes in DNA and/or RNA sequences 
(8, 9) has provided a breakthrough in this research.   
Among the human nucleotide-editing enzymes identified, only activation-induced cytidine 
deaminase (AID) has been shown to induce mutations in human host DNA sequences (10). AID 
was originally identified as an inducer of somatic hypermutations, which diversifies the variable 
regions of immunoglobulin genes in activated B cells in germinal centres (11, 12). Animal 
models with constitutive and ubiquitous expression of this nucleotide-editing enzyme, however, 
revealed that AID induces somatic mutations in various tumour-related genes, leading to the 
development of both lymphoid and non-lymphoid tumours (13, 14). Moreover, we recently 
demonstrated that pro-inflammatory cytokine stimulation induces aberrant AID expression in 
various human epithelial cells, including colonic epithelium (15), hepatocytes (6, 16), biliary 
cells (17), and gastric columnar cells (7). These findings indicate that inflammatory 
response-mediated aberrant AID expression may be a mechanism of the mutational accumulation 
required for malignant transformation in human epithelial cells (18, 19).  
Barrett’s oesophagus is a metaplastic change from the normal stratified, squamous epithelium 
of the lower oesophagus to a columnar-lined epithelium with intestinal-type differentiation (20). 
Barrett’s oesophagus is clinically significant because it is associated with high risk of 
oesophageal adenocarcinoma (21). It is well recognized that chronic duodenogastro-oesophageal 
reflux and the resultant inflammatory response play a critical role in the development of Barrett’s 
oesophagus and adenocarcinoma (21-23). Several previous studies demonstrated the involvement 
of TP53 mutations at an early stage during malignant transformation of Barrett’s oesophagus (24, 
25). In this regard, it is noteworthy that AID is aberrantly upregulated in response to 
inflammatory stimulation and AID activation induces the accumulation of multiple genetic 
alterations in TP53 in the columnar cells of the stomach (7, 26). Thus, because aberrant 
expression of AID in gastrointestinal columnar cells can be genotoxic during inflammation, we 
speculated that AID might also be involved in the pathogenesis of Barrett’s oesophageal 
adenocarcinoma. Therefore, here we investigated the expression of endogenous AID in human 
columnar epithelial cells lining Barrett’s oesophagus and Barrett’s oesophageal adenocarcinoma, 
a representative cancer that develops under chronic inflammatory conditions.  
 
Materials and methods 
Study population 
The study group comprised patients who underwent endoscopic resection for Barrett’s 
oesophageal adenocarcinoma, or endoscopic biopsy for Barrett’s oesophagus at Kyoto 
University Hospital or Saku Central Hospital between 2003 and 2005. Selection of patients 
enrolled in this study was based on the availability of a sufficient amount of tissue for analysis. 
The study group comprised 22 patients with Barrett’s adenocarcinoma (Table 1) and 6 patients 
with Barrett’s oesophagus but no oesophageal adenocarcinoma (3 men and 3 women, with a 
median age at the time of endoscopic treatment of 61 [range 38-81] years). In addition to tumour 
tissues and the surrounding nontumourous tissues of the columnar-epithelium lined Barrett’s 
oesophagus, the normal squamous cells surrounding Barrett’s epithelium were obtained from 16 
cases with Barrett’s adenocarcinoma. To validate the results of the initial analysis, we performed 
replication analyses using an independent another cohort from a different region of Japan 
(Shimane University). This second cohort included 16 patients with Barrett’s oesophagus but no 
oesophageal adenocarcinoma (7 men and 9 women, with a median age at the time of endoscopic 
treatment of 70 [range 45-80] years) and 4 patients with Barrett’s oesophageal adenocarcinoma 
(3 men and 1 woman, with a median age at the time of endoscopic treatment of 80 [range 65-85] 
years). Barrett’s oesophagus was defined by endoscopically recognizable columnar metaplasia of 
the oesophageal mucosa that was confirmed to have intestinal metaplasia by biopsy of the 
tubular oesophagus (27). Normal gastric mucosa and oesophageal squamous epithelium were 
obtained from biopsy samples of nontumourous tissues from patients with benign submucosal 
tumours of the stomach or the oesophagus, none of which showed evidence of H. pylori infection, 
and were used for AID immunostaining as a control. Written informed consent for the use of the 
resected tissues was obtained from all patients in accordance with the Declaration of Helsinki, 
and the Kyoto University Graduate School and Faculty of Medicine Ethics Committee approved 
the study. 
Immunohistochemistry 
A polyclonal antibody against human AID was generated using purified recombinant AID 
protein as an immunogen (28). Immunohistochemical staining for endogenous AID protein was 
performed as described previously (7). For semi-quantitative analysis of the immunostaining 
results, the slides were scored for AID staining independently by two evaluators (S.M. and Y.M.). 
Visual assessment of the degree and intensity of the immunoreactivity was classified as no 
staining (-), no appreciable staining; weak positive staining (+), less than 50% of the 
gastrointestinal epithelial cells or tumour cells stained with AID; and strong positive staining 
(++), more than 50% of the epithelial cells or tumour cells stained with AID.  
Cell culture and transfection 
Human non-neoplastic oesophageal squamous-derived Het-1A cells were obtained from 
American Type Culture Collection (Manassas, VA) and were grown in Bronchial Epithelial Cell 
medium supplemented with the growth factors (BEGM Bulletkit, Lonza, Basel, Switzerland). To 
express the super-repressor form of the IκB-α protein, pcDNA3-IB--del-N was made by 
inserting the cDNA fragment of human IκB-α into the BamHI-EcoRI sites of pcDNA3 
(Invitrogen, Carlsbad, CA). The cDNA fragment for pcDNA3-IκB-α-del-N (amino acids 37-317) 
was synthesized by reverse-transcription (RT) - polymerase chain reaction (PCR) with the 
oligonucleotide primers 5’-CGCGGATCCATGAAAGACGAGGAGTACGA-3’ (forward) and 
5’-CCGGAATTCTCATAACGTCAGACGCTGGC-3’ (reverse), as described previously (16). 
Lipofectamine 2000 reagent (Invitrogen) was used for transfection of the plasmids. The small 
interfering RNA (siRNA) duplex composed of 21-nucleotides against the endogenous 
noncatalytic subunit IB kinase- (IKK; also known as NEMO [NF-B essential modulator]) 
was obtained from Invitrogen (5’-UGCUCUUGAUGUGGUUGUCGUAUUC-3’, Stealth RNAi) 
and cells were treated with 0.07 nmol/ml siRNA for IKK-NEMO knockdown. A nonrelated 
control, Stealth RNAi Negative Control Duplex (Invitrogen), which lacks
 
identity with known 
gene targets, was used as a control for nonsequence-specific
 
effects. TransIT-TKO reagent 
(Mirus, Madison, WI) was used for siRNA transfection. Sodium salt deoxycholic acid (DCA) 
and the NF-B inhibitors MG132 and SN50 were purchased from Sigma (St. Louis, MO), 
Calbiochem (Darmstadt, Germany), and Biomol International LP (Plymouth Meeting, PA), 
respectively.  
Generation of stable cell lines 
Stable cell lines derived from Het-1A cells were established by a lentiviral vector-mediated AID 
expression system (15, 29). In brief, lentiviral stocks were produced in 293T cells in accordance 
with the manufacturer’s protocol (Invitrogen). Virus-containing medium was collected 48 h post- 
transfection and filtered through a 0.45-m filter. Het-1A cells were cultured in virus-containing 
medium in the presence of Neomycin (Sigma, St. Louis, MO) until colonies of stably transfected 
clones grew. Genomic DNA was extracted from the cells derived from the three independent 
cultured colonies 8 weeks after viral transduction.  
Subcloning and sequencing of tumour-related genes 
The primer sets for amplification of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene 
were: 5’- GAGGCCGATCCAGGTCAT -3’ (forward) and 5’- TTTACGGTAGTGGGGGAAGG 
-3’ (reverse). The primer sets for amplification of the TP53 gene were: 5’- 
CCCTTCCCAGAAAACCTACC -3’ (forward) and 5’- CCTCATTCAGCTCTCGGAAC -3’ 
(reverse). Amplification of the target sequences was performed using high-fidelity Phusion Taq 
polymerase (Finnzymes, Espoo, Finland), and the products were subcloned into a pGEM-T Easy 
vector (Promega, Madison, WI). The resulting plasmids were subjected to sequence analysis 
using a 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA). 
Quantitative real-time RT-PCR 
Human AID gene expression was determined by quantitative real-time RT-PCR using a Light 
Cycler 480 and Fast Start Universal Probe Master (Roche, Mannheim, Germany)(7). The 
6-carboxyfluorescein (FAM)-labelled probe specific for human AID was 
5´–TCGGCGTGAGACCTACCTGTGCTAC–3´. Standard curves for AID were generated for 
every target using a 10-fold serial dilution series of five independent transcripts derived from 
BL2-lymphoma cells that contain a high expression level of endogenous AID. To assess the 
quantity of isolated RNA as well as the efficiency of cDNA synthesis, target cDNAs were 
normalized to the endogenous mRNA levels of the housekeeping reference gene 18S ribosomal 
RNA (18S rRNA) (15). For simplicity, ratios are represented as relative values compared with 
expression levels in a lysate from control cells. The PCR procedure was performed at least three 
times for each sample, and results are expressed as box plots. 
Statistical analysis 
Statistical differences in AID expression levels were analyzed using the Kruskal-Wallis H-test 
with Bonferroni correction. Statistical significance was evaluated using the 2 test for sequence 
analyses, and the 2 test with Bonferroni correction for immunostaining analyses. Values of 
P < 0.05 were considered statistically significant except when using the Bonferroni correction. 
 
Results 
Endogenous AID expression is upregulated in the columnar epithelial cells lining 
human Barrett’s oesophagus and oesophageal adenocarcinoma cells. 
To clarify the expression and localization of AID protein in human oesophageal epithelium 
under physiological and pathological conditions, immunohistochemistry was performed using a 
specific antibody against human AID. Specificity of the antibody in immunostaining was 
confirmed by control staining performed on germinal centres of human mesenteric lymph nodes 
containing mostly activated B cells (6). First, weak or no immunostaining for AID protein was 
observed in the columnar cells from the normal gastric mucosa that did not exhibit inflammatory 
changes, consistent with our previous findings (7) (Figure 1A and Table 2). Similarly, weak or 
no AID expression was observed in normal squamous epithelial cells of individuals who lacked 
histological evidence of Barrett’s oesophageal changes (Figure 1A and Table 2). The normal 
squamous epithelial cells surrounding the columnar-lined Barrett’s epithelial cells were weakly 
positive or negative for AID immunostaining (Figure 1B and Table 2). No AID immunostaining 
was observed in any of the tissue specimens when nonimmunized serum or phosphate-buffered 
saline was used instead of antibodies against AID (data not shown). In contrast, AID 
immunoreactivity was detected in 24 of 28 (85.7%) specimens and strong immunoreactivity for 
AID was detected in 17 of 28 (60.7%) specimens of the columnar epithelial cell-lined Barrett’s 
oesophagus (Figure 1B and Table 2). In the cancer tissues, AID immunoreactivity was detected 
in 20 of 22 (90.9%) patients, and strong expression of AID protein was present in 12 of 22 
(54.5 %) patients with Barrett’s oesophageal adenocarcinoma (Figure 2 and Table 2). The 
frequency of positivity for AID expression in Barrett’s epithelial cells was significantly higher 
than that in normal squamous epithelial cells of patients without Barrett’s oesophagus (P = 0.021, 
Table 2). Although the frequency of positivity for AID expression in cancer cells tended to be 
higher than that in normal squamous epithelial cells of patients without Barrett’s oesophagus, the 
difference was not significant (P = 0.038 [a level of P < 0.025 was considered significant], Table 
2). We validated the AID immunostaining results by analyzing the tissue specimens from another 
Japanese cohort comprising 10 subjects with normal squamous cells, 4 with Barrett’s 
adenocarcinoma, and 16 with Barrett’s columnar cells but no oesophageal adenocarcinoma 
(Supplementary Table 1). Strong AID protein expression was observed in the columnar epithelial 
cells lining Barrett’s oesophagus in 15 of 16 (94.0%) patients who did not develop oesophageal 
adenocarcinoma, and in 4 of 4 (100%) patients with Barrett’s adenocarcinoma (Supplementary 
Figure 1). The frequency of positivity for AID expression in Barrett’s epithelial cells or in cancer 
cells was significantly higher than that in normal squamous epithelial cells (P = 0.00025, P = 
0.014, respectively, Supplementary Table 1). These findings suggest that the inflammatory 
response related to the development of Barrett’s oesophagus involves aberrant AID expression in 
the columnar epithelial cells lining Barrett’s oesophagus. Regarding the effect of treatment with 
proton pump inhibitors (PPIs) on AID expression, we found no significant difference in the 
frequency of endogenous AID expression between patients with and without PPI medication 
(data not shown). 
Aberrant AID expression is induced by DCA stimulation in both human oesophageal 
squamous and gastrointestinal columnar-lined cells.  
Bile reflux, which is usually associated with acid reflux, plays a critical role in the 
pathogenesis of Barrett’s oesophagus and the development of Barrett’s oesophageal cancer (21, 
30). Several studies have demonstrated that bile acid stimulation induces the activation of 
transcriptional factor NF-B in gastrointestinal epithelial cells (31-34). We previously found that 
AID expression in gastric epithelial cells is regulated by the NF-B pathway (7); therefore, we 
investigated whether bile acid stimulation could induce AID upregulation in oesophageal 
squamous cell epithelium in vitro. Accordingly, expression of AID mRNA transcripts was 
analyzed by quantitative RT-PCR in human non-neoplastic oesophageal squamous 
epithelium-derived Het-1A cells in the absence or presence of DCA, a bile acid that has a 
putative role in the development of gastrointestinal cancer (35). Only small amounts of AID 
expression were detectable in the quiescent Het-1A cells without any stimulation. Endogenous 
AID expression, however, was induced in Het-1A cells in response to DCA treatment in a 
dose-dependent manner (Figure 3A, 3B). In addition, DCA induced a time-dependent 
transcriptional upregulation of AID mRNA in the cells, peaking at 10 hours (Figure 3C). Next 
we examined whether the DCA-mediated AID expression was achieved through the NF-B 
signalling pathway. The cells were pre-treated with the NF-B inhibitory reagents MG132 and 
SN50, followed by stimulation with DCA. Treatment with MG132 or SN50 significantly reduced 
the DCA-induced increase in AID transcripts (P<0.01, Figure 3D, 3E). Moreover, the enhanced 
AID expression induced by DCA was significantly reduced by coproduction of the negative 
regulator of NF-B, the dominant negative form of IB- kinase, in Het-1A cells (P<0.01, 
Figure 3F). In addition, DCA significantly failed to elicit an increase in AID expression in cells 
in which the endogenous noncatalytic subunit IB kinase- (IKK/NEMO) was reduced by 
siRNA (P<0.01, Figure 3G). Taken together, these findings indicate that the induction of AID 
expression in human oesophageal squamous cell epithelium by bile acid stimulation is achieved 
through the activation of NF-B. We also tested whether DCA would be also involved in the 
aberrant AID expression in gastric columnar cell-lined epithelium. Quantitative RT-PCR 
analysis clearly showed that DCA stimulation in human gastric AGS cells substantially 
upregulated AID transcripts (Supplementary Figure 2). These findings suggest that aberrant AID 
expression in the oesophageal epithelium during the progression of Barrett’s oesophagus is 
achieved by bile acid stimulation through the activation of NF-B.  
AID activation resulted in the accumulation of nucleotide alterations in tumour-related 
genes of the human oesophageal squamous epithelium-derived cells. 
We previously demonstrated that aberrant AID gene expression triggers the 
accumulation of genomic mutations in the TP53 and CDKN2A genes of the cultured human 
gastric columnar epithelial cell lining (7, 36). To clarify whether DCA-induced aberrant AID 
gene expression is genotoxic in oesophageal squamous epithelial cells, we investigated whether 
AID caused somatic mutations in the tumour suppressor genes, TP53 and CDKN2A, both of 
which have been reported to contain nucleotide alterations in human Barrett’s oesophageal 
adenocarcinoma tissues (24, 25, 37, 38). For this purpose, we established cultures of human 
non-neoplastic oesophageal squamous epithelium-derived Het-1A cells with constitutive AID 
expression using a lentiviral system (Supplementary Figure 3), followed by sequencing analyses 
performed on DNA samples extracted from the cells with or without AID activation for 8 weeks. 
Accordingly, over 40 cultured colonies carrying the amplified tumour-related gene fragments 
were randomly picked and subjected to sequence analyses. Less than one substitution per 1 x 10
4
 
nucleotides was detected in the tumour-related genes subcloned from control cells without AID 
activation (Table 3). In contrast, more nucleotide alterations appeared in CDKN2A gene of the 
cells expressing AID, while 4 of the 6 mutations emerged in CDKN2A gene were identical silent 
mutations (Table 3 and Supplementary Table 2). The nucleotide alterations induced by AID gene 
activation were also observed in the TP53 sequences, but the difference in the mutation 
frequency between the AID-expressing cells and control cells was not significant (P=0.32, Table 
3 and Supplementary Table 2). Although these findings suggest the possibility that aberrant AID 
gene expression might act as a DNA mutator for some tumour suppressor genes in human 
oesophageal squamous epithelium cells, the evidence was insufficient to reach a clear 
conclusion. 
Discussion 
Barrett’s oesophagus is the strongest known risk factor for the development of 
adenocarcinoma of the distal oesophagus (21). Various genetic alterations in relation to the 
dysregulation of cell growth and apoptosis occur during the development of Barrett’s 
oesophageal cancers (24, 25, 39). For example, TP53 is the most commonly mutated tumour 
suppressor gene and is implicated in oesophageal adenocarcinoma developing in patients with 
Barrett’s oesophagus (39). How somatic mutations accumulate through the process of 
carcinogenesis under the background of Barrett’s oesophagus, however, remains unknown. In the 
present study, we demonstrated that a recently identified DNA editing enzyme, AID, is 
upregulated in the columnar-cell epithelium of Barrett’s oesophagus, while normal gastric 
columnar cells and oesophageal squamous cells showed weak or no expression of AID protein. 
Moreover, strong AID expression was frequently observed in the tumour cells of Barrett’s 
adenocarcinoma. Considering the genotoxic activity of AID, our present findings suggest the 
aberrant AID expression enhances the susceptibility to genetic alterations in Barrett’s 
columnar-lined epithelial cells.  
Increased exposure of the oesophagus to refluxed gastric and duodenal contents has a critical 
role in the development of Barrett’s oesophagus and tumour development. The concentration of 
bile acids in the oesophageal refluxate correlates with the degree of oesophageal mucosal injury 
(22, 40). More importantly, a secondary bile acid such as DCA is implicated in various cancers 
that develop in the gastrointestinal tract (41). In oesophageal adenocarcinoma, DCA is thought to 
contribute to carcinogenesis during reflux of the gastrointestinal contents (23, 42, 43). Several 
studies report that NF-B is activated by bile acid components, resulting in the upregulation of a 
variety of genes involved in the development of metaplasia of Barrett’s oesophagus and cancer 
development (31-33, 39, 44). We previously demonstrated that NF-B enhances AID expression 
in hepatocytes, and in colonic and gastric epithelial cells (7, 15, 16). In the present study, AID 
transcriptional upregulation was induced in response to bile acid stimulation in oesophageal 
epithelial cells via the NF-B signaling pathway. Consistent with our findings, a recent paper 
demonstrated a non-linear dose response to DCA for DNA damage and NF-B activation in 
oesophageal cells (45). Thus, bile acid-mediated aberrant AID expression provides a novel link 
between gastroduodenal reflux and the increased susceptibility to carcinogenesis in Barrett’s 
oesophagus.  
Several clinical and molecular features differ markedly between squamous cell carcinoma 
and Barrett’s adenocarcinoma of the oesophagus. In Barrett’s oesophagus, the tissue undergoes a 
variety of genetic alterations and a prospective follow-up of lesions biopsied by endoscopy 
indicated that TP53 gene mutations usually occur as an early event in the molecular pathogenesis 
of Barrett’s oesophageal adenocarcinoma (39). Previous studies also demonstrated the same 
TP53 mutations in adenocarcinoma and adjacent non-cancerous Barrett’s oesophageal 
epithelium, suggesting that the TP53 mutation is an important step in the progression toward 
adenocarcinoma (25, 46). Moreover, somatic mutations of the CDKN2A gene are frequently 
observed in human Barrett’s oesophageal adenocarcinoma tissues (37, 38). Our previous findings 
of constitutive AID expression in the columnar-cell lined gastric epithelium with nucleotide 
alterations in both the TP53 and CDKN2A genes (7, 36) and submicroscopic deletions in the 
CDKN2A gene locus (36) support the hypothesis that AID expression contributes to the 
enhanced susceptibility of the columnar-cell lined epithelium in Barrett’s oesophagus to 
tumourigenesis, potentially leading to adenocarcinoma. In the present study, we found that 
constitutive expression of AID in oesophageal squamous cells might also contribute to the 
accumulation of somatic mutations in both CDKN2A and TP53 genes, however, the evidence 
was insufficient to conclude that AID was genotoxic in human oesophageal squamous cells.  
In conclusion, the present findings indicate that aberrant AID expression occurs in a 
substantial proportion of human Barrett’s epithelial and adenocarcinoma cells, suggesting that 
the genotoxicity of AID in columnar epithelial cells lining Barrett’s oesophagus contributes to 
the accumulation of genetic alterations of tumour-related genes. Our findings also revealed that 
bile acid reflux plays a critical role in aberrant AID expression in the development of Barrett’s 
oesophageal adenocarcinoma. A recent study suggested that Barrett’s oesophagus is genetically 
heterogeneous where there are multiple independent clones (47), and a distinct clonal evolution 
from metaplasia to dysplasia was observed in the human stomach (48). Thus, further analyses are 
necessary to clarify whether aberrant AID expression in Barrett’s oesophageal epithelium causes 
the genetic aberrations that contribute to expanding the clonal field of dysplasia, promoting the 
development of multiple independent subclones to enhance the risk of developing putative 
cancer cells.      
 
Figure legend 
Fig. 1.  Aberrant expression of AID protein in Barrett’s oesophagus tissue specimens. 
Representative immunostaining for endogenous AID is shown. Immunohistochemistry was 
performed on normal columnar-cell lined gastric epithelium (A; upper panels), normal 
oesophageal squamous epithelium (A; lower panels), Barrett’s oesophagus (case #1 and #2, B; 
top and middle panels), and squamous cells surrounding Barrett’s epithelium (B; bottom panels). 
(original magnification ×100) 
 
Fig. 2.  AID protein production in tumour cells of Barrett’s oesophageal adenocarcinoma. 
Representative moderate-to-strong AID immunostaining is shown in the tumour tissues of 
Barrett’s oesophageal adenocarcinoma. (original magnification ×100) 
 
Fig. 3. DCA-mediated AID expression in human non-neoplastic oesophageal 
squamous-epithelium derived Het-1A cells. (A) RT-PCR for the expression of AID by Het-1A 
cells at 10 h after stimulation with 150 M of DCA (upper panel). -actin was quantified in each 
sample as an internal control (lower panel). (B) Het-1A cells were treated with various 
concentrations of DCA (0-150 M) for 10 hours. AID transcripts were measured by quantitative 
real-time RT-PCR. The expression levels were normalized to 18s ribosomal RNA (18s rRNA) as 
an endogenous control. The ratios are shown as relative value compared with the AID expression 
levels in non-stimulated Het-1A cells. (C) Time-dependent effects of DCA on AID gene 
expression. Het-1A cells were harvested and subjected to total RNA isolation immediately 
before (0) and 9, 10, 11, and 12 hours after stimulation by DCA (100 M). (D, E) Het-1A cells 
were treated with MG132 (0.15 M) (D) or SN50 (250ng/ml) (E) for 2 hours and treated with 
DCA (150 M) for 10 hours. AID transcripts were analyzed by quantitative real-time RT-PCR. 
(F) pcDNA3-IB--del-N (IB [Mutant]) was transfected into Het-1A cells and then treated 
with DCA (150 M) for 10 hours. Empty vector was used as a control. Total RNA was isolated 
from each cell and the expression levels of AID mRNA were measured by quantitative real-time 
RT-PCR. (G) siRNA targeting IKK (IKK siRNA) or control siRNA (CTR siRNA) were 
transfected into Het-1A cells, followed by DCA stimulation for 10 hours. Total RNA was 
isolated from each cell and the expression levels of AID mRNA were measured by quantitative 
real-time RT-PCR. *, P < 0.01.  
  
Supplementary material 
Supplementary Figure 1. 
Aberrant expression of AID protein in Barrett’s oesophagus and Barrett’s oesophageal 
adenocarcinoma tissue specimens of the second patient group. Representative immunostaining 
for endogenous AID is shown. Immunohistochemistry was performed on normal gastric 
columnar-lined epithelium (A; upper panels), normal oesophageal squamous epithelium (A; 
lower panels), and Barrett’s oesophagus (case #1 and #2, B; upper and lower panels). (original 
magnification ×100) (C) Representative moderate-to-strong AID immunostaining is shown in 
the tumour tissues of Barrett’s oesophageal adenocarcinoma. (original magnification ×100) 
Supplementary Figure 2. 
AID expression by DCA in human gastrointestinal columnar-lined epithelial cells. (A) Human 
gastric epithelium-derived AGS cells were treated with various concentrations of DCA (0-100 
M) for 10 hours. AID transcripts were measured by quantitative real-time RT-PCR. The 
expression levels were normalized to 18s rRNA as an endogenous control. The ratios are shown 
as relative value compared with the AID expression levels in non-stimulated AGS cells. (B) 
Time-dependent effects of DCA on AID gene expression. AGS cells were harvested and 
subjected to total RNA isolation immediately before (0) and 9, 10, 11, and 12 hours after 
stimulation by DCA (50 M).  
Supplementary Figure 3. 
RT–PCR for the expression of AID (upper panel) by control Het-1A cells (CTR), Het-1A cells at 
10 hours after stimulation with DCA (DCA), and Het-1A cells with constitutive AID expression 
using a lentiviral system (AID). -actin (lower panel) was quantified for each sample as an 
internal control. 
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Table 2. Semiquantitation of AID immunoreactivity in normal columnar cells,  




Specimens with AID Immunoreactivity 
Cell types (-) (+) (++) 
Normal columnar cells 12 8 4 0 
Normal squamous cells 10 4 6 0 
Normal squamous cells 
surrounding Barrett’s 
epithelium 
16 7 9 0 
Barrett’s columnar cells 28 4 7 17 
Barrett’s adenocarcinoma 22 2 8 12 
(++) : Strongly positive, (+) : Weakly positive, (-) : Negative  
n=number of the patients 
 
P = 0.021 
P = 0.038 
Table 3. Mutation frequency of CDKN2A and TP53 genes in Het-1A cells with or without AID activation.  
 





per total bases in 









per total bases in 







 (6/22,231) 6/43  0.41/10
4
 (1/24,299) 1/47 
TP53 1.52/10
4
 (5/32,956) 5/44  0.74/10
4
 (3/40,446) 3/54 
 
CDKN2A and TP53 sequences were amplified from Het-1A cells with or without AID activation for 8 weeks,  
subcloned into the vector, and then the cultured colonies carrying the amplified tumor-related gene fragments  
were randomly picked and subjected to sequence analyses. Data represent mean mutation frequency (left),  
number of mutated bases per number of total base pairs in CDKN2A or TP53 genes sequenced (middle,  
in parentheses), and number of mutated clones per number of total clones examined (right).  
Supplementary Table1. Morita et al.  
Semiquantitation of AID immunoreactivity in normal squamous cells, Barrett’s 





Specimens with AID Immunoreactivity 
Cell types (-) (+) (++) 
Normal squamous cells 10 3 7 0 
Barrett’s columnar cells 16 0 1 15 
Barrett’s adenocarcinoma 4 0 0 4 
(++) : Strongly positive, (+) : Weakly positive, (-) : Negative  
n=number of the patients 
 
P = 0.00025 
P = 0.014 
Supplementary Table 2. Morita et al. 
Mutation patterns of CDKN2A and TP53 genes in Het-1A cells with or without AID activation.  
 





































C to T 
G to A 
G to C 
G to C 
G to C 
G to C 
T to C 





































T to C 
T to C 
del C 
T to C 
T to C 
A to G 
T to A 
G to A 
TTC (Phe) to TCC (Ser) 
TCC (Ser) to CCC (Pro) 
CAC (His) to AC (frame shift) 
GTG (Val) to GCG (Ala) 
TGT (Cys) to TGC (Cys) 
ACA (Thr) to GCA (Ala) 
GTT (Val) to GTA (Val) 
GAG (Glu) to GAA (Glu) 
       
*  - ; silent mutations that did not alter amino acid sequences 
